Silence Therapeutics (SLN) FCF Margin (2020 - 2025)
Historic FCF Margin for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to 6857.23%.
- Silence Therapeutics' FCF Margin fell 51566100.0% to 6857.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 281.06%, marking a year-over-year increase of 276700.0%. This contributed to the annual value of 156.85% for FY2024, which is 220300.0% up from last year.
- Latest data reveals that Silence Therapeutics reported FCF Margin of 6857.23% as of Q3 2025, which was down 51566100.0% from 9749.55% recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' FCF Margin registered a high of 980.01% during Q2 2021, and its lowest value of 384192.11% during Q1 2021.
- Moreover, its 5-year median value for FCF Margin was 250.31% (2022), whereas its average is 21767.18%.
- Per our database at Business Quant, Silence Therapeutics' FCF Margin surged by 2000000000bps in 2022 and then plummeted by -89900100bps in 2025.
- Quarter analysis of 5 years shows Silence Therapeutics' FCF Margin stood at 0.0% in 2021, then tumbled by -601178826bps to 287.2% in 2022, then crashed by -201bps to 865.46% in 2023, then skyrocketed by 87bps to 108.84% in 2024, then crashed by -6200bps to 6857.23% in 2025.
- Its last three reported values are 6857.23% in Q3 2025, 9749.55% for Q2 2025, and 8671.13% during Q1 2025.